|Bid||5.14 x 900|
|Ask||5.17 x 3000|
|Day's Range||5.10 - 5.20|
|52 Week Range||3.12 - 24.34|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2021 - Aug 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
DALLAS, TX / ACCESSWIRE / September 20, 2021 / Bio-Path Holdings, Inc. (NASDAQ:BPTH): The full report can be accessed by clicking on the following link: http://www.
Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.
Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients. “AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival of less than three months and a novel treatment modality is urgently needed for such patients," said Peter Nielsen, president an